Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 2/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901443 | 1.00 | FADS1 (0.46) | FADS1CXCR4L3MBTL1ALDH1A1GRM2 | |
| SCHEMBL2893733 | 0.84 | TRPV6 (0.47) | FADS1L3MBTL1ALDH1A1GRM2SMN1; SMN2 | |
| SCHEMBL2893732 | 0.84 | TRPV6 (0.47) | FADS1L3MBTL1ALDH1A1GRM2SMN1; SMN2 | |
| SCHEMBL2903907 | 0.81 | LTA4H (0.46) | FADS1ALDH1A1GRM2LTA4HKMT2A | |
| SCHEMBL8234107 | 0.81 | LTA4H (0.46) | FADS1ALDH1A1GRM2LTA4HKMT2A | |
| SCHEMBL2902024 | 0.80 | KDM4E (0.52) | FADS1L3MBTL1ALDH1A1GRM2SMN1; SMN2 | |
| SCHEMBL2902022 | 0.80 | KDM4E (0.52) | FADS1L3MBTL1ALDH1A1GRM2SMN1; SMN2 | |
| SCHEMBL2903905 | 0.80 | FADS1 (0.43) | FADS1GRM2PRSS12LTA4H | |
| SCHEMBL2901527 | 0.79 | FADS1 (0.62) | FADS1GRM2PRSS12 | |
| SCHEMBL27739543 | 0.77 | CXCR4 (0.45) | CXCR4L3MBTL1ALDH1A1SMN1; SMN2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| WO-2007078523-A2 | 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | FADS1 4353/4885CXCR4 709/4885L3MBTL1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.